Li DAI

Dr. Li DAI

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
FOFarideh Ordikhani
Farideh Ordikhani
MUMayuko Uehara
Mayuko Uehara
VKVivek Kasinath
Vivek Kasinath
LDLi DAI
Li DAI
SESiawosh K. Eskandari
Siawosh K. Eskandari
RAReza Abdi
Reza Abdi
Recent studies in cancer research have focused intensely on the antineoplastic effects of immune checkpoint inhibitors. While the development of these inhibitors has progressed successfully, strategies to further improve their efficacy and reduce their toxicity are still needed. We hypothesized that the delivery of anti–PD-1 antibody encapsulated in PLGA nanoparticles (anti–PD-1 NPs) to the spleen would improve the antitumor effect of this agent. Unexpectedly, we found that mice treated with a high dose of anti–PD-1 NPs exhibited significantly higher mortality compared with those treated with free anti–PD-1 antibody, due to the overactivation of T cells. Administration of anti–PD-1 NPs to splenectomized LT-α –/– mice, which lack both lymph nodes and spleen, resulted in a complete reversal of this increased mortality and revealed the importance of secondary lymphoid tissues in mediating anti–PD-1–associated toxicity. Attenuation of the anti–PD-1 NPs dosage prevented toxicity and significantly improved its antitumor effect in the B16-F10 murine melanoma model. Furthermore, we found that anti–PD-1 NPs undergo internalization by DCs in the spleen, leading to their maturation and the subsequent activation of T cells. Our findings provide important clues that can lead to the development of strategies to enhance the efficacy of immune checkpoint inhibitors.

28 August 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
LDLi DAI
Li DAI

6 July 2026 in Neurochemical Research
Verified
Journal Article
Closed access
HWHao Wu
Hao Wu
JXJuntao Xia
Juntao Xia
ZSZhidan Shi
Zhidan Shi
CZChu Zhang
Chu Zhang
SCShuting Chen
Shuting Chen
LHLing He
Ling He